Diagnósticos da América Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Diagnósticos da América wird ein jährliches Gewinn- und Umsatzwachstum von 101.5% bzw. 6.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 141.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.9% betragen.

Wichtige Informationen

101.5%

Wachstumsrate der Gewinne

141.5%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	29.1%
Wachstumsrate der Einnahmen	6.6%
Zukünftige Eigenkapitalrendite	5.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	27 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Benign Growth For Diagnósticos da América S.A. (BVMF:DASA3) Underpins Stock's 30% Plummet

Jun 24

Why Investors Shouldn't Be Surprised By Diagnósticos da América S.A.'s (BVMF:DASA3) 25% Share Price Plunge

May 10

Risks To Shareholder Returns Are Elevated At These Prices For Diagnósticos da América S.A. (BVMF:DASA3)

Mar 21

Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital

Feb 04

Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?

Jan 08

Insufficient Growth At Diagnósticos da América S.A. (BVMF:DASA3) Hampers Share Price

Dec 18

Diagnósticos da América (BVMF:DASA3) Is Reinvesting At Lower Rates Of Return

Sep 20

Is Diagnósticos da América (BVMF:DASA3) Using Too Much Debt?

Aug 25

Diagnósticos da América S.A. (BVMF:DASA3) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27

Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital

Apr 17

Diagnósticos da América (BVMF:DASA3) Seems To Be Using A Lot Of Debt

Mar 13

Returns On Capital At Diagnósticos da América (BVMF:DASA3) Paint A Concerning Picture

Dec 14

Results: Diagnósticos da América S.A. Delivered A Surprise Loss And Now Analysts Have New Forecasts

Apr 01

These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Reasonably Well

Mar 02

Diagnósticos da América (BVMF:DASA3) Could Be Struggling To Allocate Capital

Jan 25

Diagnósticos da América (BVMF:DASA3) Might Be Having Difficulty Using Its Capital Effectively

Oct 10

Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?

Sep 13

There Are Reasons To Feel Uneasy About Diagnósticos da América's (BVMF:DASA3) Returns On Capital

Jun 27

Diagnósticos da América (BVMF:DASA3) Has A Somewhat Strained Balance Sheet

May 31

We're Watching These Trends At Diagnósticos da América (BVMF:DASA3)

Feb 25

Shareholders of Diagnósticos da América (BVMF:DASA3) Must Be Delighted With Their 634% Total Return

Jan 03

These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Extensively

Dec 07

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:DASA3 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (BRL Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	17,282	446	1,224	2,734	5
12/31/2025	16,463	348	949	2,125	7
12/31/2024	15,392	-81	447	1,372	8
3/31/2024	14,446	-1,150	-1,209	-487	N/A
12/31/2023	14,252	-1,138	-1,775	-964	N/A
9/30/2023	14,213	-843	-1,320	-367	N/A
6/30/2023	13,869	-752	-1,308	-169	N/A
3/31/2023	13,527	-590	-1,369	-223	N/A
12/31/2022	13,129	-387	-1,165	-29	N/A
9/30/2022	12,523	-340	-523	428	N/A
6/30/2022	11,862	-177	-404	555	N/A
3/31/2022	11,178	-177	-181	724	N/A
12/31/2021	10,419	-227	392	1,298	N/A
9/30/2021	9,973	-36	-17	819	N/A
6/30/2021	9,280	-60	-112	628	N/A
3/31/2021	7,959	-85	157	903	N/A
12/31/2020	7,039	-151	11	767	N/A
9/30/2020	5,887	-191	-210	469	N/A
6/30/2020	4,986	-198	152	782	N/A
3/31/2020	4,795	-19	312	827	N/A
12/31/2019	4,365	125	195	699	N/A
9/30/2019	4,238	127	493	925	N/A
6/30/2019	4,096	158	322	726	N/A
3/31/2019	3,992	168	208	553	N/A
12/31/2018	3,933	184	231	530	N/A
9/30/2018	3,886	210	78	386	N/A
6/30/2018	3,733	175	169	453	N/A
3/31/2018	3,545	136	218	516	N/A
12/31/2017	3,399	131	N/A	653	N/A
9/30/2017	3,259	129	N/A	626	N/A
6/30/2017	3,178	152	N/A	669	N/A
3/31/2017	3,138	169	N/A	733	N/A
12/31/2016	3,041	95	N/A	842	N/A
9/30/2016	2,965	90	N/A	676	N/A
6/30/2016	2,899	39	N/A	624	N/A
3/31/2016	2,864	29	N/A	531	N/A
12/31/2015	2,794	24	N/A	489	N/A
9/30/2015	2,731	4	N/A	433	N/A
6/30/2015	2,731	38	N/A	391	N/A
3/31/2015	2,691	58	N/A	387	N/A
12/31/2014	2,698	88	N/A	459	N/A
9/30/2014	2,666	135	N/A	462	N/A
6/30/2014	2,584	127	N/A	357	N/A
3/31/2014	2,528	130	N/A	319	N/A
12/31/2013	2,448	125	N/A	255	N/A
9/30/2013	2,406	93	N/A	271	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DASA3 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (9.9%).

Ertrag vs. Markt: DASA3 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: DASA3 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: DASA3Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BR (7.2% pro Jahr).

Hohe Wachstumseinnahmen: DASA3Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DASA3Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.9%).

Diagnósticos da América Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 21% to R$7.59

Price target decreased by 13% to R$10.22

Price target decreased by 7.0% to R$11.72

Price target decreased by 9.3% to R$11.94

Price target decreased by 7.2% to R$13.56

Price target increased by 7.4% to R$14.61

Recent updates

Benign Growth For Diagnósticos da América S.A. (BVMF:DASA3) Underpins Stock's 30% Plummet

Price target decreased by 21% to R$7.59

First quarter 2024 earnings: Revenues in line with analyst expectations

Why Investors Shouldn't Be Surprised By Diagnósticos da América S.A.'s (BVMF:DASA3) 25% Share Price Plunge

Price target decreased by 13% to R$10.22

Full year 2023 earnings released

Risks To Shareholder Returns Are Elevated At These Prices For Diagnósticos da América S.A. (BVMF:DASA3)

Price target decreased by 7.0% to R$11.72

Price target decreased by 9.3% to R$11.94

Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital

Diagnósticos da América S.A. to Report Q1, 2024 Results on May 15, 2024

Diagnósticos da América S.A., Annual General Meeting, Apr 30, 2024

Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?

Insufficient Growth At Diagnósticos da América S.A. (BVMF:DASA3) Hampers Share Price

Price target decreased by 7.2% to R$13.56

Third quarter 2023 earnings released

Price target increased by 7.4% to R$14.61

Diagnósticos da América (BVMF:DASA3) Is Reinvesting At Lower Rates Of Return

Consensus EPS estimates upgraded to R$0.56 loss

Is Diagnósticos da América (BVMF:DASA3) Using Too Much Debt?

Second quarter 2023 earnings: Revenues miss analyst expectations

Diagnósticos da América S.A. (BVMF:DASA3) Looks Inexpensive But Perhaps Not Attractive Enough

Price target decreased by 13% to R$12.61

Consensus EPS estimates upgraded to R$0.56 loss

Diagnósticos da América S.A. to Report Q1, 2023 Results on May 11, 2023

First quarter 2023 earnings released: R$0.30 loss per share (vs R$0.066 profit in 1Q 2022)

Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital

Full year 2022 earnings released

Diagnósticos da América (BVMF:DASA3) Seems To Be Using A Lot Of Debt

Price target decreased by 14% to R$17.25

Price target decreased to R$23.95

Returns On Capital At Diagnósticos da América (BVMF:DASA3) Paint A Concerning Picture

Third quarter 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Price target decreased to R$29.06

Does Diagnósticos da América (BVMF:DASA3) Have A Healthy Balance Sheet?

Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital

Second quarter 2022 earnings released

Here's Why Diagnósticos da América (BVMF:DASA3) Has A Meaningful Debt Burden

Price target decreased to R$34.22

First quarter 2022 earnings: Revenues in line with analyst expectations

Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital

Insufficient new directors

Full year 2021 earnings: EPS misses analyst expectations

Results: Diagnósticos da América S.A. Delivered A Surprise Loss And Now Analysts Have New Forecasts

These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Reasonably Well

Price target decreased to R$53.69

Price target decreased to R$56.36

Diagnósticos da América (BVMF:DASA3) Could Be Struggling To Allocate Capital

Diagnósticos da América S.A. (BOVESPA:DASA3) agreed to acquire AmeriMed American Hospitals.

Diagnósticos da América S.A. (BOVESPA:DASA3) agreed to acquire CENTRO DE DIAGONÓSTICO BORIS BERENSTEIN LTDA.

Price target decreased to R$63.36

Third quarter 2021 earnings released: EPS R$0.13 (vs R$0.10 in 3Q 2020)

Price target decreased to R$70.50

Price target decreased to R$72.79

Diagnósticos da América (BVMF:DASA3) Might Be Having Difficulty Using Its Capital Effectively

Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?

Second quarter 2021 earnings released: R$0.25 loss per share (vs R$0.30 loss in 2Q 2020)

There Are Reasons To Feel Uneasy About Diagnósticos da América's (BVMF:DASA3) Returns On Capital

Diagnósticos da América S.A. (BOVESPA:DASA3) acquired Hospital da Bahia S/A for BRL 850 million.

Diagnósticos da América (BVMF:DASA3) Has A Somewhat Strained Balance Sheet

First quarter 2021 earnings released: R$0.026 loss per share (vs R$0.16 loss in 1Q 2020)

Diagnósticos da América S.A. (BOVESPA:DASA3) acquired Hospital São Domingos S.A. for $370 million.

Full year 2020 earnings released: R$0.31 loss per share (vs R$0.40 profit in FY 2019)

We're Watching These Trends At Diagnósticos da América (BVMF:DASA3)

New 90-day high: R$77.21

Shareholders of Diagnósticos da América (BVMF:DASA3) Must Be Delighted With Their 634% Total Return

HalioDx SAS Signs an Exclusive Distribution Agreement with Diagnosticos Da America SA for Immunoscore®

These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Extensively